PAR-25-056: Secondary Analysis of Existing Datasets in Heart, Lung, and Blood Diseases and Sleep Disorders (R21 Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2024.
National Institutes of Health offered grants of up to $75,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. It expected to make about 18 awards worth $75,000 in total. Applications closed on January 7, 2026.
From the official notice on Grants.gov, last changed December 30, 2024. Checked November 7, 2026.
- Award ceiling$75,000
- Total funding$75,000
- Expected awards18
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR21
- Clinical trialsNot allowed
- Funded byNHLBI, NIAAA, NIDDK
- Median yearly award$235,510
- Typical project length2 years
- R21, Exploratory/Developmental Research Grant. Early, exploratory ideas that may not have preliminary data yet, usually for up to two years. Other open R21 notices.
Projects funded under PAR-25-056 were run by National Heart Lung and Blood Institute (NHLBI, 34 projects), National Institute on Alcohol Abuse and Alcoholism (NIAAA, 1 project) and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK, 1 project). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read PAR-25-056 in the NIH Guide.
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| PAR-23-036 | November 28, 2022 | Closed January 7, 2025 | Closed |
Key dates
| Posted | December 30, 2024 |
|---|---|
| Deadline | January 7, 2026 |
| Archived by Grants.gov | February 12, 2026 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $235,510; it allows up to $75,000 per award.
- Most of the money in the 3 programs behind this notice (69% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The goal of this funding opportunity is to stimulate the use of existing human datasets for well-focused secondary analyses to investigate novel scientific ideas or new models, systems, tools, methods, or technologies that have the potential for significant impact on biomedical or biobehavioral research in areas relevant to the NHLBI mission.
Funded under PAR-25-056 so far
NIH funded 36 projects under PAR-25-056 in fiscal 2026, at 32 institutions. The median yearly award was $235,510.
Who has won Cardiovascular Diseases Research grants before
From fiscal 2021 to 2025, Cardiovascular Diseases Research (93.837) awarded $15 billion across 11,798 grant awards, an average of $1.2 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Trustees of the University of Pennsylvania | Pennsylvania | 313 | $380 million |
| Brigham & Womens Hospital Inc | Massachusetts | 274 | $374 million |
| Regents of the University of Michigan | Michigan | 277 | $355 million |
| The Trustees of Columbia University in the City of New York | New York | 207 | $335 million |
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 295 | $320 million |
Who has won Lung Diseases Research grants before
From fiscal 2021 to 2025, Lung Diseases Research (93.838) awarded $8.7 million across 5 grant awards, an average of $1.7 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The General Hospital Corporation | Massachusetts | 1 | $5.4 million |
| New England Research Institutes Inc | Massachusetts | 1 | $2.7 million |
| The Trustees of the University of Pennsylvania | Pennsylvania | 1 | $355,699 |
| University of Washington | Washington | 1 | $350,272 |
| The Trustees of Columbia University in the City of New York | New York | 1 | $319,659 |
Who has won Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders grants before
From fiscal 2021 to 2025, Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders (93.840) awarded $3.3 million across 9 grant awards, an average of $364,164 per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Regents of the University of Colorado | Colorado | 1 | $1.5 million |
| Indiana Department of Health | Indiana | 1 | $558,986 |
| Minnesota Department of Health | Minnesota | 1 | $442,754 |
| Michigan Public Health Institute | Michigan | 1 | $311,837 |
| City of Philadelphia | Pennsylvania | 1 | $251,231 |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is PAR-25-056 still open?
No. It closed on January 7, 2026.
Who can apply for Secondary Analysis of Existing Datasets in Heart, Lung, and Blood Diseases and Sleep Disorders (R21 Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Secondary Analysis of Existing Datasets in Heart, Lung, and Blood Diseases and Sleep Disorders (R21 Clinical Trial Not Allowed)?
Closed January 7, 2026. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $75,000 each. About $75,000 in total across about 18 awards.
Who has been funded under PAR-25-056?
NIH RePORTER lists 36 projects funded under PAR-25-056 in fiscal 2026, at 32 institutions. The most were at Brigham and Women's Hospital, Univ of North Carolina Chapel Hill, Duke University.
Who has won Cardiovascular Diseases Research grants before?
The largest recipients over five fiscal years were The Trustees of the University of Pennsylvania, Brigham & Womens Hospital Inc, Regents of the University of Michigan. The program made 11,798 awards worth $15 billion in that time.
Similar open grants
- Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)
- Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional)
- Developing novel theory and methods for understanding the genetic architecture of complex human traits (R21 Clinical Trial Not Allowed)
- Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
- New Approaches for Measuring Brain Changes Across Longer Timespans (R21 Clinical Trial Optional)
- Early-Stage Dissemination and Implementation Research in Communication Disorders (R21 Clinical Trial Optional)